At Avigen, we are developing the next generation of preclinical research and development services for immunotherapies, using our proprietary microfluidic platform. By assessing cellular avidity at high-throughput, we rapidly identify, sort, and isolate the most therapeutically valuable, target-specific cells from a broad pool of drug candidates.
At Avigen, we are developing the next generation of preclinical research and development services for immunotherapies, using our proprietary microfluidic platform. By assessing cellular avidity at high-throughput, we rapidly identify, sort, and isolate the most therapeutically valuable, target-specific cells from a broad pool of drug candidates.
Interested in learning more or collaborating? We are eager to partner with biotech and pharma teams focused on cellular immunotherapies for solid tumours.